Clinical Trial

MOv19-BBz CAR T Cells in FRa+ Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment with commercial checkpoint inhibitors per routine care beginning at least 28 days after receiving MOv19-BBz CAR T cells.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-04; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2025-10-08
Trial Details
NCT Number NCT07116057
Lead Sponsor University of Pennsylvania
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
Enrollment 10 participants
Start Date 2025-10-07
Primary Completion 2040-10 (estimated)
Study Completion 2040-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-18